Lyell Immunopharma (LYEL) AI Stock Analysis

• Market Cap: $317.95M
• Dividend Yield: N/A
• Average Volume (3M): 49.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.88
• Revenue Growth: 11.11%
• EPS Growth: -46.50%
• Country: US
• Employees: 300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.89
• Shares Outstanding: 19,211,203
• 10 Day Avg. Volume: 96,039
• 30 Day Avg. Volume: 49,742
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.31
• Enterprise Value/Revenue: -1.66K
• Enterprise Value/Gross Profit: -1.66K
• Enterprise Value/Ebitda: 0.50
• 1Y Price Target: $14.00
• Price Target Upside: -15.41% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 54 Neutral
• Price Target: $11.00 ▼(-33.53% Downside)

Lyell Immunopharma's overall stock score reflects a challenging financial situation with no revenue and ongoing losses, balanced by positive corporate events and moderate technical indicators. The recent funding and promising clinical trial data are significant positives, but the company's valuation remains low due to negative earnings.

Positive Factors

Strategic Funding

Securing $100 million in funding supports clinical trials and operations into mid-2027, enhancing financial stability and enabling strategic growth.

Promising Clinical Trial Data

Positive trial results for LYL314 in treating large B-cell lymphoma indicate potential for successful commercialization, strengthening market position.

Board Expansion

Expanding the board with experienced leadership can enhance strategic decision-making and governance, supporting long-term company growth.

Negative Factors

Revenue Generation Challenges

The inability to generate revenue highlights difficulties in product commercialization, posing risks to long-term financial sustainability.

Operational Losses

Persistent operational losses indicate challenges in achieving profitability, which may hinder investment in R&D and future growth.

Cash Flow Strain

Reliance on external financing for liquidity underscores cash flow challenges, potentially limiting flexibility in strategic investments.

Lyell Immunopharma Business Overview & Revenue Model

Company Description

Lyell Immunopharma (LYEL) is a biotechnology company focused on developing innovative cell therapies to treat cancer, particularly solid tumors. The company operates within the biopharmaceutical sector and utilizes its proprietary technology platform to engineer T cells for enhanced anti-tumor activity. Lyell's core products include a pipeline of cell therapy candidates aimed at improving the efficacy and safety of cancer treatments, leveraging advancements in immunotherapy.

How the Company Makes Money

Lyell Immunopharma generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments tied to clinical progress, and royalties on product sales. The company may also receive funding through government grants or research contracts aimed at advancing its therapeutic candidates. Additionally, if Lyell's therapies receive regulatory approval and reach the market, the company could generate significant revenue from the sale of its cell therapies, contributing to its overall financial performance.

Lyell Immunopharma Financial Statement Overview

Summary

Lyell Immunopharma is facing substantial financial challenges, primarily due to its inability to generate revenue and persistent operational losses. The balance sheet is relatively stronger, with a manageable level of debt and a good equity base. However, the company's cash flow situation is strained, with heavy reliance on financing for liquidity. Overall, the financial position reflects high operational risk and the need for strategic shifts to improve revenue and profitability.

Income Statement

Lyell Immunopharma has faced significant challenges in revenue generation, with revenue dropping to zero in the latest year. The company has consistently reported negative net income, resulting in negative net profit margins. The absence of revenue and persistent losses indicate financial difficulties in scaling operations or commercializing products.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, reflecting financial prudence. However, the decline in stockholders' equity over the years may indicate operational challenges. The equity ratio remains healthy, suggesting solid capital management despite operational losses.

Cash Flow

Lyell Immunopharma's cash flow statement highlights significant operating cash outflows due to ongoing losses. While free cash flow remains negative, the company has maintained a consistent level of cash reserves. The ability to generate positive cash flow from financing activities has been crucial in sustaining operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	60.00K	61.00K	130.00K	84.68M	10.65M	7.76M
Gross Profit	60.00K	61.00K	130.00K	68.22M	-3.88M	281.00K
EBITDA	-199.95M	-200.64M	-226.76M	-166.65M	-199.94M	-207.64M
Net Income	-331.40M	-342.99M	-234.63M	-4.75M	-285.50M	-198.53M
Balance Sheet
Total Assets	385.45M	490.86M	750.03M	937.56M	1.13B	908.28M
Cash, Cash Equivalents and Short-Term Investments	276.79M	370.53M	546.22M	640.15M	614.79M	612.62M
Total Debt	46.60M	58.97M	63.17M	67.70M	67.82M	54.57M
Total Liabilities	86.53M	108.03M	95.08M	104.31M	197.62M	189.84M
Stockholders Equity	298.92M	382.82M	654.95M	833.25M	929.79M	718.44M
Cash Flow
Free Cash Flow	-172.00M	-162.86M	-166.38M	-193.83M	-191.75M	-212.35M
Operating Cash Flow	-171.48M	-162.39M	-163.69M	-169.56M	-126.25M	-160.87M
Investing Cash Flow	137.54M	122.42M	184.05M	-11.54M	-121.57M	-273.52M
Financing Cash Flow	621.00K	1.33M	1.74M	10.63M	401.24M	476.79M

Lyell Immunopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Positive. The current price of 16.55 is above the 20-day moving average (MA) of 13.34, above the 50-day MA of 12.08, and above the 200-day MA of 11.08, indicating a bullish trend. The MACD of 0.97 indicates Negative momentum. The RSI at 77.48 is Negative, neither overbought nor oversold. The STOCH value of 94.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LYEL.

Lyell Immunopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYEL	54 Neutral	$317.95M	―	-76.59%	―	11.11%	-46.50%
ADCT	54 Neutral	$450.00M	-2.55	77.89%	―	15.73%	38.73%
SEER	52 Neutral	$123.95M	-1.59	-26.44%	―	12.13%	-8.23%
FDMT	52 Neutral	$407.71M	-2.35	-31.51%	―	―	―
FATE	50 Neutral	$144.16M	-0.86	-58.44%	―	-31.23%	14.92%
NKTX	39 Underperform	$151.28M	-1.44	―	―	―	26.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Lyell Immunopharma Corporate Events

Lyell Immunopharma Secures $100 Million in Private Placement

On July 24, 2025, Lyell Immunopharma entered into a Securities Purchase Agreement to raise up to $100 million through a private placement with institutional and accredited investors. The initial closing, expected around July 25, 2025, will generate approximately $50 million, with the potential for an additional $50 million upon achieving specific clinical or corporate milestones within a year. The proceeds will fund pivotal-stage clinical trials of LYL314 and support general corporate purposes, with expectations to sustain operations into mid-2027. This financial move positions Lyell to advance its clinical trials and potentially submit a Biologics License Application in 2027 for LYL314 in treating large B-cell lymphoma.

Lyell Immunopharma Announces Promising CAR T-Cell Trial Data

On June 17, 2025, Lyell Immunopharma announced new clinical data from its ongoing Phase 1/2 trial of LYL314, a CAR T-cell therapy for large B-cell lymphoma (LBCL). The trial showed promising results with high overall response rates and manageable safety profiles in both third- or later-line (3L+) and second-line (2L) settings. The company plans to initiate a randomized pivotal trial by early 2026 and has the manufacturing capacity to support clinical development and early commercial launch if approved.